State of Alaska Department of Revenue’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.8M | Sell |
31,836
-1,344
| -4% | -$596K | 0.16% | 99 |
|
|
2026
Q1 | $14.8M | Buy |
33,180
+265
| +0.8% | +$124K | 0.16% | 97 |
|
|
2025
Q4 | $14.9M | Sell |
32,915
-2,938
| -8% | -$1.27M | 0.16% | 99 |
|
|
2025
Q3 | $14M | Sell |
35,853
-9,402
| -21% | -$3.93M | 0.14% | 117 |
|
|
2025
Q2 | $20.1M | Sell |
45,255
-1,250
| -3% | -$576K | 0.22% | 73 |
|
|
2025
Q1 | $22.5M | Buy |
46,505
+720
| +2% | +$336K | 0.26% | 57 |
|
|
2024
Q4 | $18.4M | Sell |
45,785
-2,190
| -5% | -$1.02M | 0.21% | 74 |
|
|
2024
Q3 | $22.3M | Sell |
47,975
-2,370
| -5% | -$1.14M | 0.24% | 69 |
|
|
2024
Q2 | $23.6M | Buy |
50,345
+340
| +0.7% | +$148K | 0.26% | 60 |
|
|
2024
Q1 | $20.9M | Sell |
50,005
-2,890
| -5% | -$1.22M | 0.24% | 71 |
|
|
2023
Q4 | $21.5M | Sell |
52,895
-500
| -0.9% | -$185K | 0.26% | 65 |
|
|
2023
Q3 | $18.6M | Sell |
53,395
-1,255
| -2% | -$439K | 0.23% | 72 |
|
|
2023
Q2 | $19.2M | Sell |
54,650
-8,664
| -14% | -$2.92M | 0.23% | 72 |
|
|
2023
Q1 | $19.9M | Buy |
63,314
+4
| +0% | +$1.2K | 0.24% | 75 |
|
|
2022
Q4 | $18.3M | Buy |
63,310
+6,940
| +12% | +$2.12M | 0.23% | 81 |
|
|
2022
Q3 | $16.3M | Buy |
56,370
+1,598
| +3% | +$460K | 0.22% | 90 |
|
|
2022
Q2 | $15.4M | Buy |
54,772
+18,957
| +53% | +$5.07M | 0.19% | 99 |
|
|
2022
Q1 | $9.35M | Sell |
35,815
-985
| -3% | -$234K | 0.1% | 220 |
|
|
2021
Q4 | $8.08M | Sell |
36,800
-3,035
| -8% | -$590K | 0.08% | 299 |
|
|
2021
Q3 | $7.22M | Sell |
39,835
-4,513
| -10% | -$881K | 0.07% | 318 |
|
|
2021
Q2 | $8.94M | Buy |
44,348
+3,619
| +9% | +$757K | 0.09% | 263 |
|
|
2021
Q1 | $8.75M | Sell |
40,729
-1,812
| -4% | -$398K | 0.1% | 259 |
|
|
2020
Q4 | $10.1M | Sell |
42,541
-2,442
| -5% | -$560K | 0.11% | 213 |
|
|
2020
Q3 | $12.2M | Sell |
44,983
-10,876
| -19% | -$3M | 0.15% | 159 |
|
|
2020
Q2 | $16.2M | Buy |
55,859
+11,015
| +25% | +$2.99M | 0.21% | 95 |
|
|
2020
Q1 | $10.7M | Buy |
44,844
+879
| +2% | +$202K | 0.17% | 153 |
|
|
2019
Q4 | $9.63M | Sell |
43,965
-3,460
| -7% | -$700K | 0.13% | 227 |
|
|
2019
Q3 | $8.03M | Buy |
47,425
+6,890
| +17% | +$1.22M | 0.11% | 270 |
|
|
2019
Q2 | $7.43M | Buy |
40,535
+153
| +0.4% | +$26.7K | 0.12% | 186 |
|
|
2019
Q1 | $7.43M | Sell |
40,382
-630
| -2% | -$116K | 0.13% | 177 |
|
|
2018
Q4 | $6.79M | Buy |
41,012
+64
| +0.2% | +$11.1K | 0.13% | 179 |
|
|
2018
Q3 | $7.89M | Sell |
40,948
-82
| -0.2% | -$14.6K | 0.13% | 177 |
|
|
2018
Q2 | $6.97M | Buy |
41,030
+5,682
| +16% | +$881K | 0.12% | 190 |
|
|
2018
Q1 | $5.76M | Buy |
35,348
+4,270
| +14% | +$697K | 0.12% | 197 |
|
|
2017
Q4 | $4.66M | Buy |
31,078
+25,008
| +412% | +$3.7M | 0.11% | 213 |
|
|
2017
Q3 | $922K | Buy |
6,070
+4,540
| +297% | +$683K | 0.05% | 503 |
|
|
2017
Q2 | $197K | Buy |
+1,530
| New | +$184K | 0.01% | 871 |
|
Other funds holding VRTX
State of Alaska Department of Revenue's VRTX Position: Q2 2026 in Review
State of Alaska Department of Revenue reduced its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q2 2026, selling an estimated $596K and leaving 31,836 shares worth $15.8M. The position accounts for 0.16% of the portfolio, ranked #99.
State of Alaska Department of Revenue first reported a position in VRTX in Q2 2017 and has held it in 37 quarters since. The position peaked at $23.6M in Q2 2024. 1,312 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- State of Alaska Department of Revenue held 31,836 shares of Vertex Pharmaceuticals worth $15.8M as of Q2 2026.
- State of Alaska Department of Revenue sold 1,344 Vertex Pharmaceuticals shares in Q2 2026, an estimated $596K.
- Vertex Pharmaceuticals made up 0.16% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #99 holding.
- State of Alaska Department of Revenue first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 37 quarters since.
- State of Alaska Department of Revenue's Vertex Pharmaceuticals position peaked at $23.6M in Q2 2024.
- 1,312 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.